UM - RQS 2.0 with RRLs
UM - RQS 2.0 with RRLs provides a standardized evaluation framework that extends the Radiomics Quality Score to incorporate fairness, explainability, quality control, harmonization and a nine-stage Radiomics Readiness Levels (RRLs) scale to assess radiomics study rigor and support translation into precision oncology.
Key Features:
- Enhanced Evaluation Framework: Integrates fairness, explainability, quality control, and harmonization into RQS 2.0 to evaluate radiomics study design and reporting.
- Radiomics Readiness Levels (RRLs): Implements a nine-stage framework that delineates incremental development and maturity stages for radiomics research toward clinical implementation.
- Structured Clinical Translation Pathway: Provides benchmarks and a staged pathway to inform progression from basic radiomics research to clinical application in precision oncology.
Scientific Applications:
- Precision Oncology: Evaluates radiomics studies to ensure results are reliable, reproducible, and applicable to personalized cancer treatment strategies.
- Research Rigor and Quality Control: Establishes benchmarks for data quality, analytical methods, reproducibility, fairness, and explainability in radiomics research.
Methodology:
The methodology performs a comprehensive assessment of radiomics studies across dimensions including data quality, analytical methods, reproducibility, and harmonization, and assigns studies to a nine-level Radiomics Readiness Levels (RRLs) scale to track progress toward clinical readiness.
Collections
Details
- License:
- Freeware
- Maturity:
- Emerging
- Cost:
- Free of charge
- Tool Type:
- api
- Operating Systems:
- Windows, Linux, Mac
- Added:
- 11/4/2025
- Last Updated:
- 11/4/2025
Operations
Publications
Lambin P, Woodruff HC, Mali SA, Zhong X, Kuang S, Lavrova E, Khan H, Lekadir K, Zwanenburg A, Deasy J, Bobowicz M, Marti-Bonmati L, Maidment A, Dumontier M, Kinahan PE, Nobel JM, Amirrajab S, Salahuddin Z. Radiomics Quality Score 2.0: towards radiomics readiness levels and clinical translation for personalized medicine. Nature Reviews Clinical Oncology. 2025;22(11):831-846. doi:10.1038/s41571-025-01067-1. PMID:40903523.